Phosphatase and tensin homolog expression related to cetuximab effects in colorectal cancer patients: A meta-analysis

Table 1 The main characteristics of the 8 selected studies

First Author	Year	Type of study	n	Chemotherapy regimen
				Ctx only	Ctx plus iri	Ctx plus folfiri	Ctx plus folfox	Pan	Ctx plus oxa	Ctx plus oxa and cap
Sartore-Bianchi et al[3]	2009	Cohort study	110	14	74	0	0	22	0	0
Negri et al[5]	2009	Retrospective study	50	0	36	0	0	0	14	0
Laurent-Puig et al[9]	2009	Retrospective study	173	3	141	28	0	0	0	0
Loupakis et al[10]	2009	Retrospective cohort study	102	2	100	0	0	0	0	0
Perrone et al[21]	2009	Cohort study	32	0	32	0	0	0	0	0
Frattini et al[20]	2007	Cohort study	27	0	23	0	0	0	0	4
Razis et al[22]	2008	Retrospective study	72	1	13	27	18	-	-	-
Sartore-Bianchi et al[23]	2009	Cohort study	132	15	94	0	0	23	0	0

CTX: Cetuximab; Pan: Panitumumab; oxa: Oxaliplaten; cap: Capecitabine.

Table 2 Description of phosphatase and tensin homolog status

No.	Title of the study	Method
1	Analysis of PTEN, BRAF and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer	IHC
2	PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients	FISH
3	PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer	IHC
4	PTEN status in advanced colorectal cancer treated with cetuximab	FISH
5	PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies	IHC
6	PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients	IHC
7	Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study	FISH
8	Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer	IHC

PTEN: Phosphatase and tensin homolog; BRAF: V-raf murine sarcoma viral oncogene homolog; EGFR: Epidermal growth factor receptor; IHC: Immunohistochemistry; FISH: Fluorescence in situ hybridization.